Dental M&A Landscape in 2026

An Overview of Dental M&A in the UK in 2026

The UK dental market remains active in 2026 from an M&A perspective, although the nature of activity appears to be changing.

Over the last 12 to 18 months, the largest corporate consolidators have generally been more selective, with many still managing operational challenges linked to NHS contract delivery, recruitment, integration and leverage.

In their place, activity appears to have been driven by a broader group of active mid-market acquirers, including Envisage Dental, DeNovo Dental Partners, Todays Dental, Damira, Dental Mosaic and TDMP.

This has created a different consolidation landscape. Rather than activity being concentrated solely among the largest national groups, the market is increasingly being shaped by a wider universe of ambitious acquisition-led operators.

For private equity, the attraction is clear. Dentistry remains fragmented, private and mixed practices are still in demand, and a number of smaller groups have already demonstrated an ability to source and complete acquisitions.

However, the investment case is not straightforward.

The key question is where the exit comes from. If the largest corporates remain less active, investors need confidence that a platform can either attract secondary private equity interest or become sufficiently institutional, scalable and strategically relevant to appeal to a future corporate buyer.

Recruitment will also be critical. Post-Brexit, the ability to recruit, retain and train associates has become a major operational differentiator. For investors, this directly affects revenue delivery, chair utilisation, NHS contract performance and EBITDA quality.

Technology is another important factor, although perhaps less in relation to clinical delivery and more around operational efficiency. Platforms that can use technology to improve reporting, automate back-office functions, centralise administration and reduce reliance on practice-level management may be better placed to scale margin efficiently.

Revenue mix will also matter. Routine private dentistry and plan-based income are likely to be viewed as more resilient than models heavily weighted towards cosmetic or discretionary treatments. Implants remain attractive, but are still higher-ticket procedures and therefore more exposed to affordability, patient finance and consumer confidence.

The CMA review of private dentistry is unlikely, in itself, to derail M&A activity, but it will increase scrutiny around pricing transparency, treatment-plan governance and consumer-facing sales practices.

Finally, the debt backdrop matters. Dental remains attractive to lenders, but higher for longer interest rates will make acquisition strategies more expensive, potentially reducing leverage capacity and impacting acquisition pricing.

Overall, dental remains investable, but the market has become more selective. If private equity backs more mid-tier acquisition-led platforms, this could act as a catalyst for a broader increase in M&A activity across the sector.